Table 2. Associations between IHC MIUCB subtypes and clinicopathological features obtained using CK5 and CK20.
| Clinicopathological features | No (%) | CK5/CK20 | ||||
|---|---|---|---|---|---|---|
| basal | luminal | double negative | double positive | p value | ||
| All cases | 183 (100.0) | 66 (36.0) | 58 (31.7) | 21 (11.5) | 38 (20.8) | |
| Sex | ||||||
| male | 130 (71.0) | 43 (65.2) | 44 (75.9) | 16 (76.2) | 27 (71.1) | 0.564a |
| female | 53 (29.0) | 23 (34.8) | 14 (24.1) | 5 (23.8) | 11 (28.9) | |
| Tumor size* | ||||||
| ≤3.0 cm | 64 (35.4) | 16 (24.2) | 22 (39.3) | 12 (57.1) | 14 (36.8) | 0.039a |
| >3.0 cm | 117 (64.6) | 50 (75.8) | 34 (60.7) | 9 (42.9) | 24 (63.2) | |
| Multifocality | ||||||
| absent | 169 (92.3) | 66 (100.0) | 50 (86.2) | 18 (85.7) | 35 (92.1) | 0.002b |
| present | 14 (7.7) | 0 (0.0) | 8 (13.8) | 3 (14.3) | 3 (7.9) | |
| Tumoral necrosis | ||||||
| absent | 64 (35.0) | 16 (24.2) | 29 (50.0) | 7 (33.3) | 12 (31.6) | 0.025a |
| present | 119 (65.0) | 50 (75.8) | 29 (50.0) | 14 (66.7) | 26 (68.4) | |
| CIS | ||||||
| absent | 109 (59.6) | 48 (72.7) | 25 (43.1) | 15 (71.4) | 21 (55.3) | 0.005a |
| present | 74 (40.4) | 18 (27.3) | 33 (56.9) | 6 (28.6) | 17 (44.7) | |
| Squamous variant | ||||||
| absent | 134 (73.2) | 35 (53.0) | 53 (91.4) | 18 (85.7) | 28 (73.7) | <0.001a |
| present | 49 (26.8) | 31 (47.0) | 5 (8.6) | 3 (14.3) | 10 (26.3) | |
| Glandular variant | ||||||
| absent | 172 (94.0) | 61 (92.4) | 58 (100.0) | 19 (90.5) | 34 (89.5) | 0.029b |
| present | 11 (6.0) | 5 (7.6) | 0 (0.0) | 2 (9.5) | 4 (10.5) | |
| Micropapillary variant | ||||||
| absent | 144 (78.7) | 61 (92.4) | 35 (60.3) | 17 (81.0) | 31 (81.6) | <0.001a |
| present | 39 (21.3) | 5 (7.6) | 23 (39.7) | 4 (19.0) | 7 (18.4) | |
| Sarcomatoid variant | ||||||
| absent | 166 (90.7) | 56 (84.8) | 58 (100.0) | 16 (76.2) | 36 (94.7) | <0.001b |
| present | 17 (9.3) | 10 (15.2) | 0 (0.0) | 5 (23.8) | 2 (5.3) | |
| Plasmacytoid variant | ||||||
| absent | 174 (95.1) | 66 (100.0) | 51 (87.9) | 20 (95.2) | 37 (97.4) | 0.008b |
| present | 9 (4.9) | 0 (0.0) | 7 (12.1) | 1 (4.8) | 1 (2.6) | |
| PTI | ||||||
| absent/low | 91 (49.7) | 26 (39.4) | 28 (48.3) | 12 (57.1) | 25 (65.8) | 0.064a |
| moderate/intense | 92 (50.3) | 40 (60.6) | 30 (51.7) | 9 (42.9) | 13 (34.2) | |
| ITL | ||||||
| absent | 33 (18.0) | 13 (19.7) | 8 (13.8) | 6 (28.6) | 6 (15.8) | |
| low/moderate | 131 (71.6) | 41 (62.1) | 50 (86.2) | 12 (57.1) | 28 (73.7) | 0.002b |
| intense | 19 (10.4) | 12 (18.2) | 0 (0.0) | 3 (14.3) | 4 (10.5) | |
a p value obtained using Pearson’s chi-square test; b p value obtained using likelihood-ratio test. *Tumor size not available in 2 cases. Boldface values are those that are significant (p<0.05). Abbreviations: IHC, immunohistochemical; MIUCB, muscle-invasive urothelial carcinomas of the bladder; CIS, carcinoma “in situ;” PTI, peritumoral inflammation; ITL, intratumoral lymphocytes.